BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Status:
Completed
Trial end date:
2018-02-28
Target enrollment:
Participant gender:
Summary
The purpose is to investigate the maximum tolerated dose (MTD), safety and tolerability,
pharmacokinetics and efficacy of BI 836826 monotherapy in patients with relapsed or
refractory non-Hodgkin lymphoma with at least prior treatments.